Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Board Changes

8 Sep 2014 07:00

RNS Number : 0199R
Eland Oil & Gas PLC
08 September 2014
 



 

8 September 2014

 

Eland Oil & Gas PLC

("Eland" or the "Company")

 

 

Board Changes

 

 

Eland Oil & Gas (AIM: ELA), the oil and gas exploration, development and production company with an initial focus on Nigeria and West Africa, is pleased to announce that Mr. George Maxwell has been appointed as Chief Executive Officer ("CEO") with immediate effect.

 

Mr. Maxwell was formerly Chief Financial Officer of Eland and is a founder director of the Company. Prior to this, he was General Manager for Addax in Nigeria, responsible for finance, fiscal and commercial activities.

 

Mr. Les Blair will step down from the Board and as CEO to assume the new role of Strategic Advisor to the Company with immediate effect. The role, reporting to the CEO, will be to promote the Company within Nigeria, to undertake certain partner and Government related tasks on behalf of the Company and to support the CEO in specific strategic objectives.

 

The Board is also pleased to announce the appointment of Mr. Louis Castro as Chief Financial Officer ("CFO") of the Company. Prior to his appointment as CFO, Mr. Castro was a non-executive director of Eland and chair of the audit committee. He has been a director of the Company since August 2012.

 

Mr. Castro is a Fellow of the Institute of Chartered Accountants in England and Wales, having trained with Cooper and Lybrand, now PWC. He has over 25 years' experience of investment banking with a focus on advising companies worldwide in the oil & gas and mining sectors. Most recently he has been the Managing Director of Northland Capital Partners.

 

As part of the transition, Mr. Harry Wilson has assumed the position of Executive Chairman.

 

Mr Harry Wilson, Executive Chairman, commented:

 

"With production having recommenced and the recent acquisition of Ubima, our focus is now on maximising the value of our portfolio and delivering strong shareholder returns. This requires a reshaping of the senior management team and the creation of an important new Strategic Advisor role.

 

From inception of the Company, George has demonstrated exceptional commercial judgement and I am pleased that he is stepping up to lead the Company. Since joining the Company two years ago, Louis has also proven his capability to become CFO. I believe that George and Louis will together form a strong team which has the right blend of operational, commercial and financial experience to take the Company to the next stage of its development.

 

The new in-country Strategic Advisor role recognises our need to effectively liaise with our partners and Government, and promote the Company in Nigeria. Les will remain resident in Nigeria where he has an acknowledged presence and deep connections in Nigeria's oil & gas industry. He is particularly well placed to assume this important role."

 

Mr Les Blair Founder and former CEO commented:

 

"In the past four years we have succeeded in completing two very attractive asset acquisitions and bringing one, OML 40, into production. Now is a good time to refocus our individual energies into the development of these assets to their full potential".

 

For further information:

Eland Oil & Gas PLC

+44 (0) 207 016 3180

George Maxwell, CEO

Louis Castro, CFO

Edward Cozens, IR

Canaccord Genuity Limited

+44 (0) 207 523 8000

Henry Fitzgerald-O'Connor

Peter Stewart

FirstEnergy Capital LLP

+44 (0) 207 448 0200

Majid Shafiq

Khalid Ahmed

Citigate Dewe Rogerson

+44 (0) 207 638 9571

Martin Jackson

Shabnam Bashir

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAQKODPKBKBDCK
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.